Research graph
References from Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007). Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics for African American and Black people, 2025
10.3322/caac.21874 · 2025 · External reference
Cancer statistics, 2025
10.3322/caac.21871 · 2025 · External reference
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
10.1093/jnci/djae314 · 2025 · External reference
Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial
10.1093/jnci/djaa148 · 2021 · External reference
Association of race/ethnicity and the 21-gene Recurrence Score with breast cancer-specific mortality among US women
10.1001/jamaoncol.2020.7320 · 2021 · External reference
Racial/ethnic differences in 21-gene Recurrence Score and survival among patients with estrogen receptor-positive breast cancer
10.1186/s12885-024-12238-1 · 2024 · External reference
Reduction in breast cancer death with adjuvant chemotherapy among US women according to race, ethnicity, and the 21-gene Recurrence Score
10.6004/jnccn.2023.7077 · 2024 · External reference
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer
10.3109/07357907.2014.958232 · 2014 · External reference
Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer
10.1200/jco.2010.28.15_suppl.511 · 2010 · External reference
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
10.1056/nejmoa2108873 · 2021 · External reference
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
10.1056/nejmoa041588 · 2004 · External reference
Targeting CDK4/6 in breast cancer
10.1038/s12276-025-01395-3 · 2025 · External reference
Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor–positive, ERBB2-negative breast cancer: a review
10.1001/jamaoncol.2023.2000 · 2023 · External reference
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
10.1016/j.drup.2024.101103 · 2024 · External reference
Abstract PO4-10-04: treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
10.1158/1538-7445.sabcs23-po4-10-04 · 2024 · External reference
Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
10.1093/annonc/mdu042 · 2014 · External reference
Impact of the obesity epidemic on cancer
10.1146/annurev-med-051613-012328 · 2015 · External reference
Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors
10.1001/jamanetworkopen.2023.37780 · 2023 · External reference
Obesity and breast cancer prognosis: evidence, challenges, and opportunities
10.1200/jco.2016.68.4480 · 2016 · External reference
Obesity and survival among Black women and White women 35 to 64 years of age at diagnosis with invasive breast cancer
10.1200/jco.2010.34.2048 · 2011 · External reference
Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women’s Health Initiative randomized clinical trials
10.1001/jamaoncol.2015.1546 · 2015 · External reference
Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma
10.1002/1097-0142(20010815)92:4<720::aid-cncr1375>3.0.co;2-t · 2001 · External reference
Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population
10.1007/s10552-012-0115-7 · 2013 · External reference
Association of body mass index with 21-gene Recurrence Score among women with estrogen receptor–positive, ERBB2–negative breast cancer
10.1001/jamanetworkopen.2022.43935 · 2022 · External reference
Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium
10.1007/s10549-015-3353-z · 2015 · External reference
Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer
10.1002/cncr.33288 · 2021 · External reference
Aromatase inhibition in obese women: how much is enough?
10.1200/jco.2012.43.7244 · 2012 · External reference
Survival differences in Chinese versus white women with breast cancer in the United States: a SEER-based analysis
10.1200/go.20.00316 · 2020 · External reference
The landmark series: the breast cancer burden of the Asian American population and the need for disaggregated data
10.1245/s10434-023-13103-4 · 2023 · External reference
Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States
10.1001/jama.2014.17322 · 2015 · External reference
Disease characteristics and mortality among Asian women with breast cancer
10.1002/cncr.34015 · 2022 · External reference
